Oritavancin diphosphate

SIGMA/SML1586 - 98-102% (HPLC)

Synonym: LY333328 diphosphate; (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4′-chloro[l,1′-biphenyl]-4-yl)methyl]vancomycin diphosphate; LY-333328

CAS Number: 192564-14-0
Empirical Formula (Hill Notation): C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄
Molecular Weight: 1989.09
Linear Formula: C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML1586-5MG	5 mg	$119.00 1/EA	Add To Favorites
45-SML1586-25MG	25 mg	$480.00 1/EA	Add To Favorites

This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.

Properties
Descriptions
Safety Info.
Basic Data

assay	98-102% (HPLC)
color	white to off-white
form	powder
InChI	1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;21-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
InChI key	PWTROOMOPLCZHB-BHYQHFGMSA-N
Quality Level	100
SMILES string	[P](=O)(O)(O)O.[P](=O)(O)(O)O.Clc1ccc(cc1)c2ccc(cc2)CN[C@@]3([C@H]([C@@H](O[C@H](C3)O[C@H]4[C@@H](O[C@@H]([C@H]([C@@H]4O)O)CO)Oc5c6cc7cc5Oc8c(cc(cc8)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]7C(=O)N[C@@H]9c%10cc(c(cc%10)O)c%11c(cc(cc%11O)O)[C@H](NC(=O)[C@@H](NC9
storage temp.	2-8°C

Biochem/physiol Actions:	Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.
Biochem/physiol Actions:	Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens.
Disclaimer:	category 1 skin sensitizer
Packaging:	5, 25 mg in glass bottle

Symbol	GHS07
Signal word	Warning
Hazard statements	H317
Precautionary statements	P280
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	98-102% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352200

To Order From a Quote